RA
STML

Royce & Associates’s Stemline Therapeutics, Inc. STML Stock Holding History

Royce & Associates’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-6,800
Closed -$104K – 1282
2018
Q1 		$104K Hold
6,800
– – ﹤0.01% 1101
2017
Q4 		$106K Buy
+6,800
New +$90.9K ﹤0.01% 1099
2016
Q4 		– Sell
-78,679
Closed -$852K – 1117
2016
Q3 		$852K Sell
78,679
-95,500
-55% -$777K 0.01% 947
2016
Q2 		$1.18M Hold
174,179
– – 0.01% 890
2016
Q1 		$812K Buy
174,179
+15,000
+9% +$73.3K 0.01% 951
2015
Q4 		$1M Buy
159,179
+121,179
+319% +$983K 0.01% 937
2015
Q3 		$336K Buy
+38,000
New +$399K ﹤0.01% 1074

Other funds holding STML

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Royce & Associates's STML Position: Q2 2018 in Review

Royce & Associates sold out of Stemline Therapeutics, Inc. (STML) in Q2 2018, closing a stake of 6,800 shares — an estimated $104K sold.

Royce & Associates first reported a position in STML in Q3 2015 and held it in 7 quarters. The position peaked at $1.18M in Q2 2016. 91 funds tracked by Wall St. Rank hold STML as of Q2 2018.

  • Royce & Associates reported no remaining Stemline Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Royce & Associates sold 6,800 Stemline Therapeutics, Inc. shares in Q2 2018, an estimated $104K.
  • Royce & Associates first reported a position in Stemline Therapeutics, Inc. in Q3 2015 and held it in 7 quarters.
  • Royce & Associates's Stemline Therapeutics, Inc. position peaked at $1.18M in Q2 2016.
  • 91 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2018.

Based on Royce & Associates's 13F filing for Q2 2018, filed 9 Aug 2018.